Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients

Date

11 Sep 2017

Session

Gastrointestinal tumours, non-colorectal

Presenters

Ewa Carrier

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

E. Carrier1, V. Picozzi2, M.J. Pishvaian3, K. Mody4, J. Winter5, J. Glaspy6, T. Larson7, W.C. Conway8, K. Lipson1, S. Porter1, E. Kouchakji1

Author affiliations

  • 1 Clinical Development, FibroGen, 94158 - San Francisco/US
  • 2 Hematology Oncology, Virgina Mason Medical Center, Seattle/US
  • 3 Lombardi Comprehensive Cancer Center, Georgetown University, 200007 - Washington/US
  • 4 Department Of Medicine, Mayo Clinic, Jacksonville/US
  • 5 Department Of Surgery, Thomas Jefferson University, 19107 - Philadelphia/US
  • 6 Ronald Reagan Medical Center, UCLA, Los Angeles/US
  • 7 Oncology, Virginia Piper Cancer Institute, Minnesota/US
  • 8 Oncology, Ochsner Clinic Foundation, 70121 - New Orleans/US
More

Resources

Abstract 5986

Background

Pancreatic ductal adenocarcinomas (PDAC) exhibit a high degree of desmoplasia, with extensive connective tissue growth factor (CTGF) expression and extracellular matrix production1, 2. Pamrevlumab (FG-3019), anti-CTGF antibody, is evaluated in fibrotic disease and cancer. Studies in the LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) transgenic mouse model of PDAC demonstrated that pamrevlumab, in combination with gemcitabine, prolonged survival and increased tumor cell apoptosis associated with the down-regulation of the anti-apoptotic protein XIAP3.

Methods

In Phase 2 randomized study, gemcitabine/Nab-paclitaxel (G/N) +/- pamrevlumab was given to treatment-naïve locally advanced pancreatic cancer (LAPC) patients to improve resection outcomes and overall survival (OS). 33 LAPC patients were randomized 2:1 to G/N with (Arm A) (n = 22) or without (Arm B) (n = 11) pamrevlumab. Patients who completed 6 cycles of chemotherapy underwent resectability assessment by NCCN and other (CA 19-9, PET, RECIST) criteria, and, if eligible, resection with no further treatment. Patients who progressed received second-line treatment as per physician choice.

Results

No increases in SAEs or surgical complications were observed in Arm A vs Arm B. No significant difference was seen in RECIST, PET or CA 19-9 between the arms. More patients in Arm B (45%, n = 5) than in Arm A (25%, n = 3) discontinued treatment early, mainly due to progression of disease, SAE or physician choice. Of all of the patients who completed 6 cycles of treatment, 78% of patients in Arm A, and 17% of patients in Arm B were deemed resectable; and 44% in Arm A vs 17% in Arm B underwent resection. The primary reasons in patients, who scored as eligible but resected were: metastatic disease, SAE, and physician decision. An improved resection rate was associated with a trend towards improved OS in Arm A.

Conclusions

Improved resection rate combined with increased median OS in Arm A suggests that pamrevlumab is a valuable addition to neoadjuvant therapy in LAPC patients without added toxicity, and that this combination therapy may have a positive impact on OS in LAPC patients.

Clinical trial identification

NCT01890265

Legal entity responsible for the study

Fibrogen Inc.

Funding

Fibrogen Inc.

Disclosure

E. Carrier: Consultant to Targazyme Full time employee of Fibrogen. V. Picozzi: Research funding from Celgene. K. Mody: Research Support: Ipsen, Senwha, Medimmune, Tracon. J. Winter: Research grant from American Cancer Society. J. Glaspy: Consultant for Fibrogen. Research grant from Fibrogen. K. Lipson, S. Porter, E. Kouchakji: Full time employee of Fibrogen. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings